Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

西妥昔单抗 医学 多西紫杉醇 肿瘤科 内科学 卡铂 顺铂 头颈部 氟尿嘧啶 头颈部癌 化疗 放射治疗 癌症 外科 结直肠癌
作者
J. Guigay,Anne Aupérin,Jérôme Fayette,Esma Saada‐Bouzid,Cédrik Lafond,Miren Taberna,Lionnel Geoffrois,Laurent Martin,Olivier Capitain,Didier Cupissol,Hélène Castanie,Damien Vansteene,Philippe Schafhausen,Alison Johnson,Caroline Even,Christian Sire,Sophie Duplomb,Camille Evrard,Jean‐Pierre Delord,Brigitte Laguerre
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (4): 463-475 被引量:165
标识
DOI:10.1016/s1470-2045(20)30755-5
摘要

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–platinum–cetuximab) showed promising results, with a median overall survival of 14·0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum–fluorouracil–cetuximab) in this setting. Methods This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18–70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m2 was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m2 on day 1–4, cisplatin 100 mg/m2 on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m2 cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. Findings Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34·4 months (IQR 26·6–44·8) in the TPEx group and 30·2 months (25·5–45·3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5–15·7] in the TPEx group and 13·4 months [12·2–15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74–1·08]; p=0·23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001). In the TPEx group, 118 (45%) of 263 patients had at least one serious adverse event versus 143 (54%) of 265 patients in the EXTREME group. 16 patients in the TPEx group and 21 in the EXTREME group died in association with adverse events, including seven patients in each group who had fatal infections (including febrile neutropenia). Eight deaths in the TPEx group and 11 deaths in the EXTREME group were assessed as treatment related, most frequently sepsis or septic shock (four in each treatment group). Interpretation Although the trial did not meet its primary endpoint, with no significant improvement in overall survival with TPEx versus EXTREME, the TPEx regimen had a favourable safety profile. The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment. Funding Merck Santé and Chugai Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
妖孽宇发布了新的文献求助10
1秒前
aa完成签到,获得积分20
1秒前
aaaa完成签到,获得积分10
1秒前
马香芦完成签到,获得积分10
2秒前
西红柿完成签到,获得积分10
3秒前
4秒前
懵懂的冬灵完成签到,获得积分10
4秒前
碧蓝可仁完成签到 ,获得积分10
5秒前
王拉拉完成签到 ,获得积分10
5秒前
西西完成签到,获得积分10
5秒前
深情安青应助mkmimii采纳,获得10
6秒前
上官若男应助小王采纳,获得10
6秒前
bkagyin应助旦皋采纳,获得10
6秒前
Orange应助欣欣采纳,获得10
7秒前
玄学大哥完成签到,获得积分10
7秒前
7秒前
7秒前
kk完成签到,获得积分10
7秒前
ww007完成签到,获得积分10
9秒前
科研通AI5应助hahaha123213123采纳,获得10
9秒前
misstwo完成签到,获得积分10
10秒前
研友_ZzrwqZ发布了新的文献求助10
10秒前
JY'完成签到,获得积分10
11秒前
一只小鲨鱼完成签到,获得积分10
12秒前
漂亮的哈密瓜完成签到,获得积分10
12秒前
量子星尘发布了新的文献求助10
12秒前
13秒前
LL发布了新的文献求助10
13秒前
苏苏完成签到,获得积分10
14秒前
14秒前
fabc5653219完成签到,获得积分10
15秒前
hkunyu完成签到 ,获得积分10
15秒前
jiao完成签到,获得积分10
16秒前
16秒前
LIUYONG完成签到,获得积分10
17秒前
ChatGPT发布了新的文献求助10
18秒前
18秒前
小王发布了新的文献求助10
18秒前
这个大头张呀完成签到,获得积分10
18秒前
19秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029